Giulia Pellizzari

Nov 20, 2023 | bmjoncology.bmj.com | Giulia Pellizzari

One of the many impacts COVID-19 pandemic had on the UK healthcare environment was to highlight the disparities and inequalities present in the national setting in accessing healthcare and clinical trials.1 If the challenges to design more inclusive, equal and effective trial recruitment strategies were known before the pandemic, what this historic moment did was to elicit a tangible effort in revolutionising these approaches: all the major national cancer trial funders started to demand that...

Jul 25, 2023 | nature.com | James B. Spicer |Udai Banerji |Rebecca S Kristeleit |Rowan Miller |Christopher J Corrigan |Silvana Canevari | +8 more

AbstractAll antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report a Phase I dose escalation trial (NCT02546921) with the primary objective of exploring the safety and tolerability of MOv18 IgE, a chimeric first-in-class IgE antibody, in patients with tumours expressing the relevant antigen, folate receptor-alpha.

Apr 25, 2023 | nature.com | Tony Cheung |Chara Stavraka |Giulia Pellizzari |Francis Man |Hannah Gould |Andrew J. Beavil | +4 more

AbstractOutcomes for half of patients with melanoma remain poor despite standard-of-care checkpoint inhibitor therapies. The prevalence of the melanoma-associated antigen chondroitin sulfate proteoglycan 4 (CSPG4) expression is ~70%, therefore effective immunotherapies directed at CSPG4 could benefit many patients. Since IgE exerts potent immune-activating functions in tissues, we engineer a monoclonal IgE antibody with human constant domains recognizing CSPG4 to target melanoma.